Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Evaluation of drug-drug interactions has focused on ivermectin and blood stage active antimalarial drugs, and on antimalarial triple combination therapies (i.e. dihydroartemisinin-piperaquine plus mefloquine). Two clinical trials were completed in healthy volunteers to evaluate these interactions. Co-administration of ivermectin plus dihydroartemisinin-piperaquine led to increased concentrations of ivermectin, which imparted a greater mosquito-lethal effect (Clin Pharmacol Ther. 2020 May; 107(5):1221-1230). For antimalarial triple combinations, results demonstrated a significantly decreased exposure to dihydroartemisinin, when dihydroartemisinin-piperaquine was co-administered with mefloquine (Antimicrob Agents Chemother. 2019 Jul 25; 63(8):e00060-19). All combinations were demonstrated to be safe to be implemented in larger patient populations. In addition to the study in healthy volunteers a non-compartmental analysis of data from the above mentioned TRACII study showed a lower exposure of artemether, its metabolite dihydroartemisinin, and lumefantrine than co-administered with amodiaquine (Lancet. 2020 Apr 25; 395(10233):1345-1360).